Literature DB >> 7835792

The NIH Consensus Conference on Ovarian Cancer: screening, treatment, and follow-up.

E L Trimble1.   

Abstract

Entities:  

Mesh：

Year:  1994        PMID： 7835792     DOI： 10.1006/gyno.1994.1332

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  7 in total

1.  Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.

Authors:  Steven J Skates; Mark H Greene; Saundra S Buys; Phuong L Mai; Powel Brown; Marion Piedmonte; Gustavo Rodriguez; John O Schorge; Mark Sherman; Mary B Daly; Thomas Rutherford; Wendy R Brewster; David M O'Malley; Edward Partridge; John Boggess; Charles W Drescher; Claudine Isaacs; Andrew Berchuck; Susan Domchek; Susan A Davidson; Robert Edwards; Steven A Elg; Katie Wakeley; Kelly-Anne Phillips; Deborah Armstrong; Ira Horowitz; Carol J Fabian; Joan Walker; Patrick M Sluss; William Welch; Lori Minasian; Nora K Horick; Carol H Kasten; Susan Nayfield; David Alberts; Dianne M Finkelstein; Karen H Lu
Journal:  Clin Cancer Res       Date:  2017-01-31       Impact factor: 12.531

Review 2.  Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment.

Authors:  Fiona Kew; Khadra Galaal; Andrew Bryant; Raj Naik
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

3.  A meta-analysis on the impact of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors with invasive implants.

Authors:  Ines Vasconcelos; Jessica Olschewski; Ioana Braicu; Jalid Sehouli
Journal:  Oncologist       Date:  2015-01-19

Review 4.  Prophylactic surgery and other strategies for reducing the risk of familial ovarian cancer.

Authors:  Elizabeth Swisher
Journal:  Curr Treat Options Oncol       Date:  2003-04

5.  Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers.

Authors:  Jason K Sa; Jae Ryoung Hwang; Young-Jae Cho; Ji-Yoon Ryu; Jung-Joo Choi; Soo Young Jeong; Jihye Kim; Myeong Seon Kim; E Sun Paik; Yoo-Young Lee; Chel Hun Choi; Tae-Joong Kim; Byoung-Gie Kim; Duk-Soo Bae; Yeri Lee; Nam-Gu Her; Yong Jae Shin; Hee Jin Cho; Ja Yeon Kim; Yun Jee Seo; Harim Koo; Jeong-Woo Oh; Taebum Lee; Hyun-Soo Kim; Sang Yong Song; Joon Seol Bae; Woong-Yang Park; Hee Dong Han; Hyung Jun Ahn; Anil K Sood; Raul Rabadan; Jin-Ku Lee; Do-Hyun Nam; Jeong-Won Lee
Journal:  Genome Biol       Date:  2019-11-26       Impact factor: 13.583

6.  CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery.

Authors:  Fang Wang; Yanfen Ye; Xia Xu; Xuehui Zhou; Jinhua Wang; Xiaoxiang Chen
Journal:  J Ovarian Res       Date:  2013-02-13       Impact factor: 4.234

7.  Factors Influencing the Discordancy Between Intraoperative Frozen Sections and Final Paraffin Pathologies in Ovarian Tumors.

Authors:  Hung Shen; Heng-Cheng Hsu; Yi-Jou Tai; Kuan-Ting Kuo; Chia-Ying Wu; Yen-Ling Lai; Ying-Cheng Chiang; Yu-Li Chen; Wen-Fang Cheng
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.